SHP2 Inhibitor + KRAS G12C Inhibitor Combination

About Navire Pharma

Navire Pharma is a private, pre-revenue biotech founded in 2015, specializing in SHP2 inhibitor therapeutics for oncology. Its core technology platform targets the SHP2 phosphatase, a key node in multiple oncogenic signaling pathways like RAS-MAPK, with the goal of addressing tumor resistance. The company's most advanced assets are in early clinical development, primarily focused on non-small cell lung cancer and other solid tumors. Navire's strategy involves leveraging its expertise to develop best-in-class inhibitors that could be used alongside existing targeted therapies or immunotherapies.

Therapeutic Areas